TEAMWork Mobile Application in Helping with Talking to Employers and Medical Staff about Work in Patients with Stage I-III Breast Cancer Undergoing Chemotherapy
This trial studies how well the TEAMWork mobile application works in helping with talking to employers and medical staff about work in patients with stage I-III breast cancer who are undergoing or planning to undergo chemotherapy. The TEAMWork mobile application may help doctors learn more about how being treated for breast cancer affects patients' employment, and how to help patients with breast cancer keep their jobs during and after treatment.
Inclusion Criteria
- PATIENT USABILITY TESTING: History of a cancer diagnosis
- PATIENT USABILITY TESTING: At least 18 years of age
- PATIENT USABILITY TESTING: Male or female
- PATIENT USABILITY TESTING: The ability to give informed consent in English or Spanish
- PATIENT USABILITY TESTING: Able to use and read a smartphone (iPhone or Android)
- PATIENT USABILITY TESTING: Has a smartphone (iPhone or Android)
- COMMUNITY USABILITY TESTING: At least 18 years of age
- COMMUNITY USABILITY TESTING: Male or female
- COMMUNITY USABILITY TESTING: The ability to give informed consent in English or Spanish
- COMMUNITY USABILITY TESTING: Able to use and read a smartphone (iPhone or Android)
- COMMUNITY USABILITY TESTING: Has a smartphone (iPhone or Android)
- FOCUS GROUP AND INTERVIEW: Completed chemotherapy treatment for stage I-III breast cancer
- FOCUS GROUP AND INTERVIEW: Age 18 to 64 (inclusive) at time of diagnosis
- FOCUS GROUP AND INTERVIEW: Female
- FOCUS GROUP AND INTERVIEW: Paid employment (full time or part time) in the three months prior to diagnosis or at time of consent to Memorial Sloan Kettering (MSK) protocol #10-071 (principal investigator [PI]: Blinder)
- FOCUS GROUP AND INTERVIEW: The ability to give informed consent in English or Spanish
- FOCUS GROUP AND INTERVIEW: Able to use and read a smartphone (iPhone or Android)
- FOCUS GROUP AND INTERVIEW: Has a smartphone (iPhone or Android)
- FOCUS GROUP AND INTERVIEW: COHORT 2: Participant was covered by Emergency Medicaid at the time of diagnosis and/or at any point during their treatment for breast cancer
- RANDOMIZED CONTROLLED TRIAL (RCT): Localized invasive breast cancer (not stage 0 or stage IV) per EMR or breast cancer (not stage 0 or stage IV) per self report for community participants * If electronic medical record does not specify stage and patient is undergoing (neo)adjuvant chemotherapy, assume stage is I, II or III
- RCT: Planning to undergo or undergoing adjuvant or neoadjuvant chemotherapy per EMR or planning to undergo or undergo chemotherapy per self-report for community participants
- RCT: Age 18 to 64 (inclusive)
- RTC: Female
- RCT: Employment status of full time or part time (those who are on disability leave/medical leave, and other unique employment circumstances at the PI’s discretion are eligible)
- RCT: Language preference as English or Spanish
- RCT: Able to use and read a smartphone or tablet (e.g. iPad, iPhone or Android)
- RCT: Has access to a smartphone or tablet (e.g. iPad, iPhone or Android)
Exclusion Criteria
- RCT: Participants or family members who are participating in MSK Immigrant Health and Cancer Disparities Service (IHCD) studies related to social determinants of health
Additional locations may be listed on ClinicalTrials.gov for NCT03572374.
Locations matching your search criteria
United States
New Jersey
Basking Ridge
Middletown
New York
Bronx
Commack
New York
Rego Park
Uniondale
West Harrison
PRIMARY OBJECTIVES:
I. To refine the TEAMWork application (App) through usability testing and focus groups in English- and Spanish-speaking women.
II. To evaluate the effect of the TEAMWork App on job retention after completion of adjuvant therapy for breast cancer among English- and Spanish-speaking women who were employed pre-diagnosis and plan to undergo chemotherapy but have low confidence in requesting workplace accommodations.
IIa. To evaluate whether the effect of the app on job retention varies by characteristics including chemotherapy regimen, symptom burden, race/ethnicity, language, and job type.
III. To evaluate the effect of the TEAMWork App on confidence in asking an employer for accommodations and on receipt of workplace accommodations during and following adjuvant therapy.
IV. To evaluate the effect of the TEAMWork App on patient efficacy in communicating with the oncology provider and self-reported symptom burden during and following adjuvant therapy.
EXPLORATORY OBJECTIVE:
I. To evaluate the effect of the TEAMWork App on treatment adherence.
OUTLINE:
PART I: Patients take part in a focus group over 1.5 hours.
PART II: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive TEAMWork mobile application consisting of 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu includes videos and has a list of features from which patients can choose to learn about a particular topic.
GROUP II: Patients receive information booklet that includes the information in the mobile application that can practicably be converted to paper.
After completion of study, patients are followed up at 4 months, and at 1, 2, and 3 years.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorVictoria Susana Blinder
- Primary ID18-217
- Secondary IDsNCI-2018-01426
- ClinicalTrials.gov IDNCT03572374